Semaphorin 4A (Sema4A) has an essential role in photoreceptor survival. In humans, mutations in Sema4A are thought to contribute to retinal degenerative diseases. Here we generate a series of knock-in mouse lines with corresponding mutations (D345H, F350C or R713Q) in the Sema4A gene and find that Sema4AF350C causes retinal degeneration phenotypes. The F350C mutation results in abnormal localization of the Sema4A protein, leading to impaired endosomal sorting of molecules indispensable for photoreceptor survival. Additionally, protein structural modelling reveals that the side chain of the 350th amino acid is critical to retain the proper protein conformation. Furthermore, Sema4A gene transfer successfully prevents photoreceptor degeneration in Sema4AF350C/F350C and Sema4A−/− mice. Thus, our findings not only indicate the importance of the Sema4A protein conformation in human and mouse retina homeostasis but also identify a novel therapeutic target for retinal degenerative diseases.
The major cause of adult blindness in industrialized countries is the progressive dysfunction and death of retinal photoreceptors. Retinal photoreceptor degeneration is one of the most genetically heterogeneous disorders in humans. Inherited forms of retinal photoreceptor degeneration are defined by their predominantly monogenic inheritance and are a common cause of visual impairment, with a prevalence of ~1 in 3,000 (refs 1, 2). Although many genes have been linked to a photoreceptor degenerative disease phenotype, the mechanisms by which most of these genes lead to this disorder are not fully understood.
Semaphorins were initially identified as axonal guidance cues that determine the direction and migration of neurons during neurogenesis3. In addition, accumulating evidence has shown that semaphorins have diverse functions in other physiological and pathogenic processes, including vascular development4, tumour progression5, heart development6 and immune responses7,8. Semaphorin 4A (Sema4A) is a class IV transmembrane-type semaphorin. Previously, Rice et al.9 reported that inserting a gene-trap vector into intron 11 of the mouse Sema4A gene resulted in the loss of retinal photoreceptors. Consistent with their findings, we recently determined that Sema4A-deficient (Sema4A−/−) mice display severe photoreceptor degeneration10. Notably, we demonstrated that Sema4A, which is expressed in retinal pigment epithelial (RPE) cells, regulates distinct endosomal sorting pathways that are critical for photoreceptor survival and phototransduction during the transition between daylight and darkness10. Thus, Sema4A is thought to be one of the genes responsible for retinal degenerative diseases. In fact, three mutations, D345H (345GAC→CAC; D→H), F350C (350TTT→TGT; F→C) and R713Q (713CGG→CAG; R→Q), in the human Sema4A gene have been reported in patients with retinal degenerative diseases based on sequencing of the Sema4A gene from 190 unrelated patients suffering from a variety of retinal degenerative diseases, including retinitis pigmentosa and cone rod dystrophy11. However, it has not been determined whether these mutations are really responsible for retinal degeneration, and if so, how mutations in the Sema4A gene induce pathogenesis.
In this report, we generated a series of knock-in mouse lines with mutations (D345H, F350C and R713Q) in the Sema4A gene in order to examine the impact of these mutations on the pathogenesis of retinal degenerative diseases. We found that a single point mutation, F350C, caused severe degeneration in photoreceptor cells. In addition, we determined that the pathogenicity of the F350C mutation is due to severe structural defects and resultant mis-localization of the Sema4A protein in RPE cells, which led to impaired endosomal sorting. Furthermore, we provided evidence that Sema4A is a therapeutic target for retinal degenerative diseases using virus-mediated gene therapy.
Sema4AF350C/F350C mice exhibit retinal degeneration
We first generated a series of knock-in mouse lines that express wild-type (WT) or mutated Sema4A proteins. As the amino-acid sequence of Sema4A is highly conserved between humans and mice, with the 345th, 350th and 713th amino acids being identical, we constructed four knock-in vectors to generate mice with these respective mutations (Fig. 1a). Full-size cDNA fragments of WT Sema4A or mutated Sema4A (D345H, F350C or R713Q) fused to enhanced green fluorescent protein (EGFP) at the carboxy terminus were inserted into exon 2 and exon 3 of the Sema4A gene. This series of homozygous knock-in mice appeared normal at birth, developed normally and were fertile, as it is the case for Sema4A−/− mice. Every mutant protein was expressed in tissues (Fig. 1b).
Photoreceptor homeostasis is functionally and mechanically supported by RPE cells, which closely interact with photoreceptors via microvilli that interdigitate with the adjacent photoreceptor outer segment. RPE cells perform specialized functions for photoreceptors, including supplying nutrients and factors that protect against light-induced oxidative damage12. Immunohistochemistry with an anti-green fluorescent protein (GFP) antibody showed that Sema4A localized at the apical surface of the plasma membrane in RPE cells (Fig. 1c), which is consistent with our previous studies10. We then examined the histopathology of the respective Sema4A knock-in mice. Of note, only Sema4AF350C/F350C mice exhibited changes in retinal photoreceptors that were compatible with Sema4A−/− mice (Fig. 2a). The outer segment of photoreceptors in Sema4AF350C/F350C retina was severely disrupted at 2 weeks of age, followed by a complete loss of photoreceptors at 4 weeks of age (Supplementary Fig. S1). Electroretinography (ERG) monitoring confirmed these histological findings (Fig. 2b). A TdT-mediated dUTP nick end labelling (TUNEL) assay demonstrated that Sema4AF350C/F350C retina exhibited a marked increase in the number of apoptotic cells in the outer nuclear layer under illumination (Fig. 2c), which was similar to that observed in Sema4A−/− mice10. By contrast, Sema4AD345H/D345H and Sema4AR713Q/R713Q mice did not exhibit retinal degeneration (Fig. 2a). In addition, Sema4AD345H/+, Sema4AF350C/+ and Sema4AR713Q/+ mice did not show any retinal defects (Supplementary Fig. S2). Although compound D345H/F350C heterozygous mutations were reported to be associated with retinal degenerative diseases in humans11, knock-in mice carrying these mutations did not exhibit this phenotype (Fig. 2a). These findings indicate the importance of the 350th amino acid in the function of Sema4A protein.
The Sema4AF350C protein is mis-localized in RPE cells
These findings raise the question of why the F350C mutation results in impaired Sema4A functions, even though the expression of this mutant protein is not severely impaired in tissues (Fig. 1b). To elucidate this question, we examined protein localization in the retina using the same series of mutant Sema4A knock-in mice. Interestingly, immunohistochemistry revealed that the Sema4AF350C-EGFP protein was abnormally localized. Sema4AF350C-EGFP remained in the cytosol, while Sema4AWT-EGFP, Sema4AD345H-EGFP and Sema4AR713Q-EGFP localized to the surface of RPE cells in the retinas of mutant knock-in mice (Fig. 3a) and to the surface of primary cultured RPE cells derived from mutant knock-in mice (Fig. 3b). To confirm these findings, we prepared constructs expressing Sema4AWT-EGFP, Sema4AD345H-EGFP, Sema4AF350C-EGFP and Sema4AR713Q-EGFP for in vitro assays, and examined their cellular localization by introducing them into COS-7 cells or a human RPE-derived cell line, ARPE-19 cells. As expected, the Sema4AF350C-EGFP protein failed to reach the plasma membrane, while Sema4AWT-EGFP, Sema4AD345H-EGFP and Sema4AR713Q-EGFP localized to the plasma membrane (Fig. 3c). These results indicate that photoreceptor degeneration in Sema4AF350C/F350C mice was due to defects in Sema4A protein localization and distribution in RPE cells.
In addition, the Sema4AF350C protein did not impair the cell surface expression of the Sema4AWT protein (Fig. 4a), indicating that the F350C mutation does not function in a dominant-negative manner.
The Sema4AF350C protein results in impaired endosomal sorting
Moreover, Blue-native PAGE (BN-PAGE) analysis, which separates proteins under native conditions13, indicated that the structural integrity of Sema4A was compromised by F350C mutation; the Sema4AF350C protein behaved as high-molecular-weight aggregates on the gel, whereas the other Sema4A proteins migrated as distinct bands corresponding to the monomer and dimer (Fig. 5a). In order to explore more about the critical roles of F350 in the Sema4A structure, we prepared a series of Sema4A expression constructs that harbour various mutations in this position, including methionine, tyrosine, glycine and serine (F350M, F350Y, F350G and F350S, respectively). We introduced these expression constructs into ARPE-19 cells or COS-7 cells and examined whether the respective proteins could reach the cell surface. Interestingly, F350M and F350Y, but not F350G and F350S, could reach the plasma membrane (Fig. 5b). The result indicates that the mutation is tolerated when F350 is substituted with relatively large amino acids (that is, Met and Tyr), while replacement with small residues (that is, Cys, Gly, and Ser) is detrimental.
Recently, the determination of the crystal structures of semaphorin ectodomains, particularly in complex with their cognate plexin receptors, has led to remarkable progress in our understanding of the structural basis for semaphorin function14,15,16,17,18. To investigate the structural background of the differential effect of each mutation on the function, we built a structural model of mouse Sema4A ectodomain using the structure of human Sema4D fragment as a template (PDB ID: 1OLZ)15. In the model, F350 is located far from the predicted plexin-binding surface (Fig. 5d), suggesting that the functional defect exhibited by the mutants is not attributable to a specific loss of plexin-binding activity. Closer inspection of the model revealed that the residue is only partially exposed on the protein surface (Fig. 5d), with its large aromatic side chain nestled in a pocket created by many hydrophobic residues (Fig. 5e). Therefore, mutation of this residue to amino acids with smaller side chain would create significant vacant space in the protein interior, which is known to harm the overall stability of the protein19. Thus, our study clearly demonstrated the importance of the correct cellular localization of Sema4A in RPE cells, which can be fundamentally disturbed by the lack of only a few atoms in a critical amino-acid residue.
We previously demonstrated that Sema4A exerts a unique function in the retina, namely by regulating the endosomal sorting of molecules that are indispensable for the phototransduction and survival of photoreceptors10. Sema4A regulates two distinct endosomal sorting pathways. First, Sema4A sorts prosaposin, an important antiapoptotic factor, to the plasma membrane of RPE cells, where it is subsequently secreted via exosomes. Second, Sema4A sorts retinoid-binding proteins, including cellular retinaldehyde-binding protein (CRALBP), which is involved in the transport of retinoids to photoreceptors during dark adaptation and the retinoid cycle, to the surface of RPE cells. Indeed, similar to Sema4A−/− cells, RPE cells from Sema4AF350C/F350C retinas expressed lower levels of prosaposin in secreted H2O2-induced exosomes (Fig. 5f), indicating that endosomal sorting is impaired in Sema4AF350C/F350C RPE cells as well as Sema4A−/− RPE cells. CRALBP also failed to distribute to the surface of RPE cells (Fig. 5h). These results indicate that the endosomal sorting function of Sema4A was severely impaired by the F350C mutation.
Sema4A gene transfer prevents retinal degeneration
For potential gene therapy, we finally performed lentivirus-mediated Sema4A gene transfer experiments to determine whether this method could prevent retinal photoreceptor degeneration. According to a previously established transfer method for RPE cells20, we prepared lentiviral expression constructs for Sema4AWT-FLAG and Sema4AF350C-FLAG. To confirm the expression patterns of these constructs, we transfected 293T cells with each lentiviral construct. As shown in Supplementary Fig. S3, Sema4AF350C-FLAG did not reach the cell surface. Next, the Sema4AWT-FLAG- or Sema4AF350C-FLAG-expressing lentiviral suspension was injected into the subretinal space of 1-week-old Sema4A−/− or Sema4AF350C/F350C mice using a transvitreous approach (Fig. 6a). Three weeks after injection, the eye tissues were fixed and sectioned. In mice injected with lentiviral vectors expressing Sema4AWT-FLAG, the layer of photoreceptor cells was substantially preserved on the injected side alone in both Sema4A−/− and Sema4AF350C/F350C retinas (Fig. 6b). In contrast, injecting with lentiviral vectors expressing Sema4AF350C-FLAG did not prevent photoreceptor degeneration in either Sema4A−/− or Sema4AF350C/F350C mice. Immunohistochemistry confirmed that the injection of these lentiviral vectors resulted in sustained expression of the Sema4AWT-FLAG or Sema4AF350C-FLAG proteins specifically in RPE cells (Fig. 6b). In addition, injecting lentiviral vectors expressing Sema4AWT-FLAG restored ERG responses to some extent in Sema4A−/− and Sema4AF350C/F350C retinas (Fig. 6d). Notably, we observed long-term preservation of the photoreceptor layer, lasting at least 4 months after gene transfer (Fig. 7). Thus, we demonstrated a successful means to prevent retinal photoreceptor degeneration using lentivirus-mediated Sema4A gene transfer.
Here we highlighted a novel pathogenic trait of retinal degenerative diseases by analysing a series of knock-in mice with Sema4A mutations, which are thought to contribute to human retinal degenerative disease11. Among these mice, only Sema4AF350C/F350C mice exhibited light-induced retinal degeneration that occurred immediately after birth, which is similar to that observed in Sema4A−/− mice (Fig. 2a). In addition, a protein structural modelling and mutational analysis of the Sema4A protein revealed that the side-chain volume of the 350th amino acid is critical for its proper conformation and function in the endosomal sorting of molecules indispensable for photoreceptor survival (Fig. 5d–i). We further determined that Sema4A has therapeutic effects in retinal degenerative diseases using virus-mediated gene therapy (Fig. 6).
Recently, we reported that Sema4A mediated the exosomal release of prosaposin and endosomal sorting of retinoid-binding proteins, including CRALBP, in RPE cells10. The finding that Sema4A functions as an intracellular guide for specific molecules was highly significant because semaphorins and their receptor plexins were previously shown to function as extracellular guidance molecules3. Indeed, our structural modelling of the Sema4A protein indicated that the plexin-binding site is distant from the 350th amino acid (Fig. 5d), suggesting that this mutation does not block this ligand–receptor interaction. This notion is consistent with our previous finding that mice lacking Sema4A receptors exhibited no apparent retinal defects10. However, as Plexin-D1-deficient mice die soon after birth21, we cannot exclude a possibility that the defects are potentially mediated by interacting receptors. Further careful evaluation would be required to determine the pathogenesis.
In addition, BN-PAGE analysis showed that the F350C mutation causes intracellular aggregation of the Sema4A protein, probably within the endoplasmic reticulum, in RPE cells (Fig. 5a). Thus, it appears that this structural defect prevents the protein from being properly transported to its cellular compartments. In this context, the present findings support the notion that Sema4A can function as an ‘intracellular navigator’ that releases molecules essential for photoreceptor survival. It is also noteworthy that the Sema4AF350C protein did not affect the expression of the Sema4AWT and Sema4AD345H proteins (Fig. 4), indicating that this mutated protein does not function in a dominant-negative manner.
Sema4AD345H/D345H and Sema4AR713Q/R713Q mice did not show a disease phenotype in our study (Fig. 2a). In our mouse Sema4A ectodomain model, D345 is located in an α-helix with its side chain well exposed to the solvent and R713 is located in the short cytoplasmic tail region, which is unlikely to form a structural domain. Therefore, both D345H and R713Q do not seem to cause major structural destabilization, which is further supported by the normal cell surface expression of these mutants (Fig. 3a). However, we cannot completely exclude the possibility that these mutations contribute to the pathogenicity of human retinal degenerative diseases. There are several possibilities for the differences between our study using mutant mice and a previous human study11. First, humans have a longer lifespan than mice, and thus F350C heterozygosity (with D345H) in humans may ultimately induce retinal degenerative disease owing to reduced expression of functional Sema4A proteins. Second, we should carefully evaluate the findings of the human study because this report only sequenced the Sema4A gene but did not definitively exclude the possible involvement of other genetic factors. In addition, the human report did not include the phenotypes of F350C homozygotes. Third, slight amino-acid differences between human and mouse Sema4A might contribute to the fragility of the human Sema4A protein structure with a D345H mutation. It has been recently reported that transiently expressed human Sema4AD345H mutant protein showed altered intracellular localization in human RPE cell lines22. Additionally, as large-scale sequential analyses of patient DNA have not been performed except for Pakistani individuals11, further studies will be required to determine whether patients in other racial groups possess the same mutation.
We presented evidence that virus-mediated Sema4A gene transfer was successful in an animal model (Fig. 6). Thus, it is theoretically possible to treat this type of retinal degenerative disease with gene therapy, if performed immediately after birth. Recently, considerable progress has been made in the development of gene therapy for retinal degenerative diseases using recombinant adeno-associated virus or lentivirus-based vectors23. Currently, RPE65, which encodes the retinoid isomerase enzyme and causes Leber congenital amaurosis, is the first and only gene that has been successfully treated by gene transfer therapy in human eyes24,25,26,27,28,29. As Sema4A gene transfer displayed a strong curative effect that was comparable to that of RPE65 at least in the histology in animal models, it appears that Sema4A might be a candidate therapy for retinal degenerative diseases. However, although ERG responses could be detected after gene transfer (Fig. 6d), the levels of responses were relatively low compared to those in WT retinas (Fig. 2b). Deeper investigations would be necessary to reveal the extent of the gene transfer efficacy. As retinal degenerative diseases are caused by many genetic changes, Sema4A gene therapy might be limited to a subset of patients carrying Sema4A genetic changes, such as the F350C mutation. However, considering the endosomal sorting function of Sema4A for various molecules that are indispensable for retinal homeostasis, it is possible that Sema4A replacement gene therapy might be efficacious in a wider subset of patients with retinal degenerative diseases. Further studies are required to assess the potential of Sema4A gene therapy.
Collectively, we demonstrated that Sema4A is required for photoreceptor survival. We determined that a point mutation in the Sema4A gene causes retinal degenerative disease, which was further supported by structural modelling analyses. The F350C mutation reduces the amino-acid side-chain volume and creates a significant vacant space in the protein interior, which is known to affect the overall stability of the protein19 and may lead to the precipitation of the protein into non-functional aggregates. Furthermore, photoreceptor degeneration could be rescued by Sema4A gene supplementation in an animal model. Our findings provide a novel therapeutic target for retinal degenerative diseases.
Sema4A−/− mice (previously established30) as well as all knock-in mice (Sema4AWT/WT mice, Sema4AD345H/D345H mice, Sema4AF350C/F350C mice, Sema4AR713Q/R713Q mice, Sema4AD345H/F350C mice, Sema4AWT/+ mice, Sema4AD345H/+ mice, Sema4AF350C/+ mice and Sema4AR713Q/+ mice) and WT mice (Sema4A+/+ mice) with the same genetic background (C57BL/6J) were housed under a 12-h light/12-h dark cycle (60 lux at the cage level). All animal procedures were performed in accordance with institutional guidelines.
Construction of the expression vector and site-directed mutagenesis
The cDNA sequence encoding full-length Sema4A (amino acids 1–760) was generated by PCR and then ligated into pEGFP-N3 (Clontech, Palo Alto, CA) or p3xFLAG-CMV-14 (Sigma-Aldrich Co., Milwaukee, WI). Various mutant constructs (Sema4AD345H-EGFP, Sema4AF350C-EGFP, Sema4AR713Q-EGFP, Sema4AF350M-EGFP, Sema4AF350Y-EGFP, Sema4AF350G-EGFP, Sema4AF350S-EGFP and Sema4AF350C-FLAG) were generated from Sema4AWT-EGFP or Sema4AWT-FLAG using a QuikChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer’s protocol.
Gene targeting strategy
DNA fragments were isolated from Sema4AWT-EGFP, Sema4AD345H-EGFP, Sema4AF350C-EGFP and Sema4AR713Q-EGFP constructs. To construct targeting vectors (for Sema4AWT/WT, Sema4AD345H/D345H, Sema4AF350C/F350C and Sema4AR713Q/R713Q mice), the 3.1-kb fragments encoding full-length WT or mutant Sema4A cDNA containing EGFP at the C-terminus were placed into exon 2 and exon 3 in the intact Sema4A alleles. The Herpes simplex virus thymidine kinase (HSV-tk) gene was inserted to select against random integration. The linearized targeting plasmid DNA was electroporated into ES cells. After selecting with G418, resistant colonies were screened for homologous recombination of the Sema4A-targeted allele by PCR and Southern blot analysis. The clones with homologous recombination were identified and isolated. These ES cells were injected into blastocysts from C57BL/6J mice. The blastocysts were transferred to pseudopregnant ICR foster mothers, and chimeric males were obtained. Subsequently, chimeric males and WT females were mated to produce heterozygous, targeted mice.
ARPE-19 cells, COS-7 cells and 293T cells were grown in DMEM supplemented with 10% fetal calf serum. RPE cells were isolated from 10-day-old mice for primary cultures following an experimental procedure that was previously described31. Briefly, enucleated eyecups were treated with 2% dispase (Invitrogen, San Diego, CA) and 0.5% trypsin/EDTA (Gibco BRL Life Technologies, Rockville, MD), and the isolated RPE cells were seeded into fibronectin-coated cell culture dishes (BD BioCoat) (BD Bioscience, San Jose, CA) and grown in DMEM containing 10% fetal bovine serum at 37 °C. RPE cells were successfully subcultured using 0.5% trypsin/EDTA every 7 days for 1 month.
The antibodies used to detect Sema4A were previously described30. The other antibodies used in this study include anti-GFP (Cell Signaling Technology Inc., Danvers, MA), anti-FLAG (Cell Signaling Technology Inc., Danvers, MA), anti-prosaposin (Abcam, Cambridge, UK) and anti-CRALBP (Abcam, Cambridge, UK). Cells were transfected using FuGENE HD (Roche Applied Science, Indianapolis, IN) and then incubated for 2 days, collected and lysed in lysis buffer (50 mM Tris–HCl at pH 8.0, 250 mM NaCl, 5 mM EDTA, 1% NP-40, 0.25% Na-deoxycholate and 1 mM NaF) for immunoprecipitation and immunoblot analyses, which were performed using standard protocols.
SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and BN-PAGE
For SDS–PAGE, samples were boiled for 5 min in SDS–PAGE sample buffer containing 0.125 mM Tris–HCl, pH 6.8, 20% glycerol, 4% SDS, 10% 2-mercaptoethanol and 0.004% bromophenol blue. The protein samples were loaded onto NuPAGE 4–12% Bis–Tris gels (Invitrogen, San Diego, CA). BN-PAGE systems were purchased from Invitrogen, and sample preparation and electrophoresis were performed according to the manufacturer’s instructions. For immunoblot analysis, the gel was electroblotted onto a PVDF membrane, which was blocked in 5% skim milk and incubated with an anti-Sema4A antibody followed by a goat anti-rabbit secondary antibody.
Immunohistochemistry of paraffin-embedded specimens
Eyecup specimens were fixed in 4% paraformaldehyde and routinely processed for paraffin embedding. Paraffin-embedded specimens were cut into 4-μm-thick sections and stained using the immunoperoxidase procedure. After antigen retrieval with a Pascal pressurized heating chamber (DAKO A/S, Glostrup, Denmark), the sections were treated with Melanin bleach Kit (Polysciences Inc., Warrington, PA) to remove melanin from RPE cells, incubated with the indicated antibodies and then treated with ChemMate EnVision kit (DAKO A/S, Glostrup, Denmark). DAB (DAKO A/S, Glostrup, Denmark) was used as a chromogen.
Immunohistochemistry of frozen specimens
Frozen sections of 4% paraformaldehyde-fixed eyecups of 8 μm thickness were prepared. The sections were treated with Melanin bleach Kit (Polysciences Inc., Warrington, PA) to remove melanin from RPE cells, incubated with a blocking solution (5% BSA in PBS containing 0.5% Triton X-100) for 1 h, and then stained overnight with the indicated antibodies. Confocal images were obtained using an LSM 5 EXCITER (Ver 4.2) confocal inverted microscope (Carl Zeiss MicroImaging, Jena, Germany).
TUNEL assay systems (DeadEnd Fluorometric TUNEL system) were purchased from Promega (Madison, WI). Prepared frozen sections were processed according to the manufacturer’s protocol. Sections were imaged using an LSM 5 EXCITER (Ver 4.2) confocal inverted microscope (Carl Zeiss MicroImaging, Jena, Germany).
Conventional full-field ERGs were recorded in vivo using a PuREC system with two built-in white LED contact lens electrodes (Mayo, Aichi, Japan). Mice were dark-adapted overnight and all subsequent procedures were performed under dim red light. Before the ERG recordings, mice were anaesthetized and placed on a heating pad held at 37 °C throughout the experiments. The pupils were dilated with a cocktail of 0.05% tropicamide and 0.05% phenylephrine hydrochloride. 0.5% hydroxyethyl cellulose was applied to the eyes to maintain corneal hydration. Needle electrodes placed subcutaneously in the forehead and tail served as reference and ground electrode, respectively. Single-flash recordings were performed at a light intensity of 2.0 log cd s m−2 using a sampling frequency of 1,253 Hz and a flash duration of 13.3 ms. The band-pass filter was set between 0.3 and 500 Hz. In addition, the obtained data were low-pass filtered at 300 Hz using a PuREC software (Mayo, Aichi, Japan).
Homology model building
Sequence alignments of the ectodomain portions of mouse Sema4A (residues 36–650) and human Sema4D (residues 24–648) were generated using CLUSTALW32. Homology model building was performed with the programme MODELLER33 using the human Sema4D ectodomain structure (PDB ID: 1OLZ)15 as a template.
Preparation of lentiviral vectors
C-terminal FLAG-tagged Sema4A cDNA fragments with or without the F350C mutation were isolated and amplified by PCR from the Sema4AWT-p3xFLAG-CMV-14 or Sema4AF350C- p3xFLAG-CMV-14 constructs. The PCR primers contained an AgeI site at the 5′-terminus and EcoRI site at the 3′-terminus. Primer sequences are described in Supplementary Table S1. This fragment was digested with AgeI and EcoRI, and subsequently subcloned into the AgeI and EcoRI sites of CSII-CMV-MCS (RIKEN, Tokyo, Japan). The titres of the Sema4AWT-FLAG and Sema4AF350C-FLAG lentiviral vectors were determined by quantitative RT-PCR using viral RNA from 293T cells infected with these vectors. After the virus was concentrated by ultracentrifugation, titres of 5 × 107 infectious units ml−1 for the Sema4AWT-FLAG lentiviral vector and 1.3 × 107 infectious units ml−1 for the Sema4AF350C-FLAG lentiviral vector were obtained.
In vivo delivery of lentiviral vectors
Infant mice (1 week of age) were anaesthetized. The eyeball was exposed by an incision in the eyelid, parallel to the future edge of the open eyelid. Subretinal injections were performed under an operating microscope. A small incision was made in the sclera, and 2 μl of undiluted vector suspension (titres of 1.3–5 × 107 infection units ml−1 on 293T cells) was injected through the incision into the subretinal space using a glass capillary connected to a 10-μl syringe.
How to cite this article: Nojima, S. et al. A point mutation in Semaphorin 4A associates with defective endosomal sorting and causes retinal degeneration. Nat. Commun. 4:1406 doi: 10.1038/ncomms2420 (2013).
Pacione, L. R. et al. Progress toward understanding the genetic and biochemical mechanisms of inherited photoreceptor degenerations. Annu. Rev. Neurosci. 26, 657–700 (2003) .
Wright, A. F. et al. Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait. Nat. Rev. Genet. 11, 273–284 (2010) .
Kolodkin, A. L., Matthes, D. J. & Goodman, C. S. . The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell 75, 1389–1399 (1993) .
Serini, G. et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424, 391–397 (2003) .
Neufeld, G. & Kessler, O. . The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat. Rev. Cancer 8, 632–645 (2008) .
Toyofuku, T. et al. Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial growth factor receptor type 2. Genes Dev. 18, 435–447 (2004) .
Suzuki, K., Kumanogoh, A. & Kikutani, H. . Semaphorins and their receptors in immune cell interactions. Nat. Immunol. 9, 17–23 (2008) .
Takamatsu, H. & Kumanogoh, A. . Diverse roles for semaphorin-plexin signaling in the immune system. Trends Immunol. 33, 127–135 (2012) .
Rice, D. S. et al. Severe retinal degeneration associated with disruption of Semaphorin 4A. Invest. Ophthalmol. Vis. Sci. 45, 2767–2777 (2004) .
Toyofuku, T. et al. Endosomal sorting by Semaphorin 4A in retinal pigment epithelium supports photoreceptor survival. Genes Dev. 26, 816–829 (2012) .
Abid, A. et al. Identification of novel mutations in the SEMA4A gene associated with retinal degenerative diseases. J. Med. Genet. 43, 378–381 (2006) .
Lamb, T. D. & Pugh, E. N. Jr. . Dark adaptation and the retinoid cycle of vision. Prog. Retin. Eye Res. 2, 307–380 (2004) .
Schägger, H. & von Jagow, G. . Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. Anal. Biochem. 199, 223–231 (1991) .
Antipenko, A. et al. Structure of the semaphorin-3A receptor binding module. Neuron 39, 589–598 (2003) .
Love, C. A. et al. The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D. Nat. Struct. Biol. 10, 843–848 (2003) .
Janssen, B. J. et al. Structural basis of semaphorin–plexin signaling. Nature 467, 1118–1122 (2010) .
Nogi, T. et al. Structural basis for semaphorin signalling through the plexin receptor. Nature 467, 1123–1127 (2010) .
Liu, H. et al. Structural basis of semaphorin-plexin recognition and viral mimicry from Sema7A and A39R complexes with PlexinC1. Cell 142, 749–761 (2010) .
Atwell, S., Ultsch, M., De Vos, A. M. & Wells, J. A. . Structural plasticity in a remodeled protein-protein interface. Science 278, 1125–1128 (1997) .
Miyoshi, H., Takahashi, M., Gage, F. H. & Verma, I. M. . Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl Acad. Sci. USA 94, 10319–10323 (1997) .
Gitler, A. D., Lu, M. M. & Epstein, J. A. . PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. Dev. Cell 7, 107–116 (2004) .
Tsuruma, K. et al. SEMA4A mutations lead to susceptibility to light irradiation, oxidative stress, and ER stress in retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 53, 6729–6737 (2012) .
Bainbridge, J. W., Tan, M. H. & Ali, R. R. . Gene therapy progress and prospects: the eye. Gene Ther. 13, 1191–1197 (2006) .
Van Hooser, J. P. et al. Rapid restoration of visual pigment and function with oral retinoid in a mouse model of childhood blindness. Proc. Natl Acad. Sci. USA 97, 8623–8628 (2000) .
Acland, G. M. et al. Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28, 92–95 (2001) .
Jacobson, S. G. et al. Identifying photoreceptors in blind eyes caused by RPE65 mutations: prerequisite for human gene therapy success. Proc. Natl Acad. Sci. USA 102, 6177–6182 (2005) .
Bainbridge, J. W. et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N. Engl. J. Med. 358, 2231–2239 (2008) .
Maguire, A. M. et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N. Engl. J. Med. 358, 2240–2248 (2008) .
Maguire, A. M. et al. Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374, 1597–1605 (2009) .
Kumanogoh, A. et al. Nonredundant roles of Sema4A in the immune system: defective T cell priming and Th1/Th2 regulation in Sema4A-deficient mice. Immunity 22, 305–316 (2005) .
Geisen, P. et al. Characterization of barrier properties and inducible VEGF expression of several types of retinal pigment epithelium in medium-term culture. Curr. Eye Res. 31, 739–748 (2006) .
Larkin, M. A. et al. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947–2948 (2007) .
Eswar, N. et al. Protein structure modeling with MODELLER. Methods Mol. Biol. 426, 145–159 (2008) .
Zamyatnin, A. A. . Protein volume in solution. Prog. Biophys. Mol. Biol. 24, 107–123 (1972) .
This study was supported by research grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (T.T. and A.K.); Funding Programme for Next-Generation World-Leading Researchers (NEXT Program); and CREST (A.K.).
The authors declare no competing financial interests.
About this article
Cite this article
Nojima, S., Toyofuku, T., Kamao, H. et al. A point mutation in Semaphorin 4A associates with defective endosomal sorting and causes retinal degeneration. Nat Commun 4, 1406 (2013). https://doi.org/10.1038/ncomms2420
This article is cited by
Nature Reviews Rheumatology (2018)
Nature Communications (2014)
Nature Reviews Drug Discovery (2014)
Nature Reviews Immunology (2013)